Onlit 4 Tablet

About Onlit 4 Tablet

Onlit 4 is a tablet containing ondansetron 4 mg. It is used to prevent and treat nausea and vomiting linked to cancer chemotherapy, radiotherapy, or surgery. It belongs to a group of anti-emetic medicines.

There are 74 brands of Ondansetron listed in Bangladesh. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.

What is Onlit 4 Tablet?

Onlit 4 is an anti-emetic tablet made by Asiatic Laboratories Ltd. It contains ondansetron 4 mg, a medicine that blocks a serotonin receptor involved in the vomiting reflex. Doctors prescribe it to prevent nausea and vomiting during cancer chemotherapy and radiotherapy, and to prevent and treat nausea and vomiting after surgery. It is not a general stomach settler and does not speed up gut movement. The dose and course are chosen by the doctor based on the person's condition and treatment plan.

Uses of Onlit 4

Onlit 4 is used to prevent nausea and vomiting caused by emetogenic cancer chemotherapy, including repeat courses. It is also used to prevent and treat nausea and vomiting after surgery, and to prevent nausea and vomiting caused by radiotherapy. It does not treat other causes of vomiting, so the doctor should be told about the person's symptoms and medical history.

How to use Onlit 4

Take Onlit 4 exactly as the doctor tells you. The doctor decides the dose, how often to take it, and how long to continue it; those details are not fixed for everyone. Swallow the tablet with water, or follow any other instruction the doctor or pharmacist gives. Do not change the dose or stop early on your own. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Onlit 4

Common side effects reported with ondansetron include headache, constipation and diarrhoea, and most are mild or moderate. Rash has been reported in some people receiving it with chemotherapy. Flushing or warmth, hiccups, and changes in liver enzymes have also been reported. Rarely, serious reactions such as anaphylaxis, bronchospasm, fast heartbeat, chest pain, low potassium and shortness of breath have been reported. Tell your doctor promptly about any side effect.

Safety and precautions

Tell your doctor if you have had an allergic reaction to ondansetron or to other similar anti-nausea medicines. Onlit 4 is not a substitute for nasogastric suction and should not be used for that purpose. After abdominal surgery or during chemotherapy, it may hide a developing ileus or gastric distension, so the doctor should be told about ongoing vomiting or bloating. The safety of ondansetron in pregnancy and breastfeeding should be discussed with the doctor, as human data are limited. People with liver problems or other illnesses should ask the doctor before use.

Frequently asked questions

What is Onlit 4 used for and what kind of medicine is it?

Onlit 4 is an anti-emetic tablet containing ondansetron 4 mg. It is used to prevent and treat nausea and vomiting caused by cancer chemotherapy, radiotherapy, or surgery. It blocks a serotonin receptor involved in the vomiting reflex. The doctor decides the dose and course.

Which medicines may interact with Onlit 4?

Ondansetron is broken down by liver enzymes, so medicines that change these enzymes may change how long it stays in the body. It should not be used with apomorphine. Tell your doctor or pharmacist about all other medicines, including those bought without a prescription, before taking Onlit 4.

Is Onlit 4 safe in pregnancy or breastfeeding?

Animal studies with ondansetron did not show harm to the fetus, but there are not enough well-controlled studies in pregnant women. It is not known whether ondansetron passes into breast milk. Ask your doctor about the risks and benefits before using Onlit 4 during pregnancy or breastfeeding.

Who should ask a doctor before taking Onlit 4?

Anyone with a known allergy to ondansetron or similar anti-nausea medicines should ask the doctor first. People with liver problems, or those who have had abdominal surgery, should also check with the doctor. Ask the doctor or pharmacist about any other health condition or medicine before starting Onlit 4.

Indications

Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

Pharmacology

Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.

Dosage & Administration

Chemotherapy-Induced Nausea and Vomiting-
Adults, Pediatric patients (6 months to 18 years):
  • 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
  • Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting-
Adults:
  • 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
  • 4 mg orodispersible tablet: 16 mg
  • Injection: 4 mg
Pediatrics (>40 kg): Injection: 4 mg
Pediatrics (40 kg): Injection: 0.1 mg/kg

Chemotherapy-induced Nausea and Vomiting-
Adults/Geriatric/Child of 12 years or over:
  • Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
  • Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.


Oral solution:

Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
  • For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
  • For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
  • For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
  • 20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia


Oral Soluble Film:

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
  • Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
  • Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
  • Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
  • Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
  • Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.

Interaction

Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.

Contraindications

Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.

Side Effects

Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.

Pregnancy & Lactation

Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.

Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.

Precautions & Warnings

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.

Storage Conditions

Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.

Alternative brands of Ondansetron

Other brands with the same generic name, cheapest first.

See all 74 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.